Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer

Exclusion Criteria

• •Prior therapy with taxane or with epidermal growth factor receptor (EGFR) inhibitors
• •More than one prior chemotherapy treatment
• •Clinically significant cardiac disease
• •Major surgery within 4 weeks of the start of study treatment
• •Evidence of central nervous system (CNS) metastases or carcinomatous meningitis or history of uncontrolled seizures, central nervous system disorders.
• •Uncontrolled serious medical or psychiatric illness
• •Pregnant or breast-feeding women
• •Other active malignancy
• •Inability to swallow tablets or evidence of a gastrointestinal malabsorption syndrome
• •Known severe hypersensitivity to Iressa
• •Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, or St. John's wort.
• •History of severe hypersensitivity reaction to drugs formulated with polysorbate 80
• •Any evidence of clinically active interstitial lung disease
• •Ascites requiring paracentesis